eldecalcitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	5169	104121-92-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eldecalcitol ED-71	an analog of vitamin D for the treatment of osteoporosis Molecular weight: 490.73 Formula: C30H50O5 CLOGP: 6.09 LIPINSKI: 1 HAC: 5 HDO: 4 TPSA: 90.15 ALOGS: -4.67 ROTB: 10

Molecule

Description

Molfile Inchi Smiles

Synonyms:

eldecalcitol
ED-71

an analog of vitamin D for the treatment of osteoporosis

Molecular weight: 490.73
Formula: C30H50O5
CLOGP: 6.09
LIPINSKI: 1
HAC: 5
HDO: 4
TPSA: 90.15
ALOGS: -4.67
ROTB: 10

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2011	PMDA	Chugai Pharmaceutical Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	242.78	24.28	95	5003	35028	63448896
Renal impairment	207.99	24.28	113	4985	88242	63395682
Hypercalcaemia	182.99	24.28	73	5025	28249	63455675
Interstitial lung disease	131.27	24.28	74	5024	61834	63422090
Femoral neck fracture	99.58	24.28	34	5064	8489	63475435
Spinal compression fracture	89.34	24.28	36	5062	14247	63469677
Cerebral infarction	80.52	24.28	39	5059	23854	63460070
Osteomyelitis	74.44	24.28	38	5060	25982	63457942
Fall	74.13	24.28	121	4977	392213	63091711
Hepatic function abnormal	64.37	24.28	39	5059	37103	63446821
Fatigue	59.26	24.28	3	5095	888025	62595899
Cardiac failure	58.47	24.28	52	5046	89090	63394834
Atypical femur fracture	57.20	24.28	20	5078	5352	63478572
Hypocalcaemia	51.63	24.28	32	5066	31681	63452243
Femur fracture	45.90	24.28	33	5065	41723	63442201
Drug ineffective	45.31	24.28	14	5084	1044751	62439173
Altered state of consciousness	45.01	24.28	27	5071	25203	63458721
Acute phase reaction	44.87	24.28	9	5089	274	63483650
Pneumonia bacterial	42.95	24.28	19	5079	9446	63474478
Aortic dissection	39.83	24.28	12	5086	2006	63481918
Haemorrhage subcutaneous	39.18	24.28	13	5085	2970	63480954
Decreased appetite	36.30	24.28	69	5029	250983	63232941
Platelet count decreased	35.28	24.28	45	5053	116077	63367847
Physical deconditioning	35.02	24.28	9	5089	840	63483084
Oesophageal carcinoma recurrent	32.72	24.28	5	5093	28	63483896
Pancytopenia	31.73	24.28	39	5059	96894	63387030
Pyelonephritis	31.64	24.28	19	5079	17759	63466165
Hypercalcaemic nephropathy	30.95	24.28	4	5094	4	63483920
Disseminated intravascular coagulation	30.43	24.28	19	5079	19032	63464892
Pneumocystis jirovecii pneumonia	29.90	24.28	18	5080	16896	63467028
Pyrexia	27.96	24.28	92	5006	470386	63013538
Pemphigoid	27.82	24.28	13	5085	7331	63476593
Herpes zoster	26.69	24.28	33	5065	82429	63401495
Compression fracture	26.25	24.28	12	5086	6436	63477488
Blood pressure decreased	26	24.28	29	5069	64993	63418931
Drug eruption	25.56	24.28	20	5078	28674	63455250
Upper respiratory tract inflammation	25.35	24.28	9	5089	2514	63481410
Liver disorder	25.08	24.28	26	5072	53661	63430263
Anaemia	24.69	24.28	65	5033	293365	63190559

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	53.39	28.88	29	949	65253	34890700
Hypercalcaemia	35.20	28.88	14	964	15454	34940499
Renal impairment	29.61	28.88	23	955	94490	34861463
Hypocalcaemia	29.13	28.88	14	964	24275	34931678

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	241.72	20.75	100	6209	43126	79694953
Hypercalcaemia	195.02	20.75	83	6226	38347	79699732
Renal impairment	178.81	20.75	126	6183	157657	79580422
Interstitial lung disease	156.27	20.75	102	6207	112498	79625581
Femoral neck fracture	106.23	20.75	37	6272	9947	79728132
Spinal compression fracture	83.86	20.75	36	6273	16922	79721157
Cerebral infarction	79.92	20.75	48	6261	45628	79692451
Osteomyelitis	69.32	20.75	39	6270	32826	79705253
Hypocalcaemia	66.14	20.75	44	6265	49880	79688199
Fall	64.73	20.75	128	6181	487501	79250578
Cardiac failure	62.78	20.75	69	6240	154773	79583306
Atypical femur fracture	58.16	20.75	20	6289	5169	79732910
Hepatic function abnormal	57.39	20.75	47	6262	73060	79665019
Fatigue	52.88	20.75	6	6303	929721	78808358
Femur fracture	46.26	20.75	32	6277	38620	79699459
Pneumonia bacterial	43.65	20.75	24	6285	19307	79718772
Drug ineffective	43.09	20.75	16	6293	1080897	78657182
Acute phase reaction	42.45	20.75	9	6300	367	79737712
Decreased appetite	37.27	20.75	83	6226	342335	79395744
Altered state of consciousness	36.12	20.75	29	6280	43793	79694286
Platelet count decreased	35.80	20.75	59	6250	194605	79543474
Upper respiratory tract inflammation	35.52	20.75	13	6296	4022	79734057
Pyelonephritis	34.54	20.75	21	6288	20367	79717712
Herpes zoster	33.45	20.75	39	6270	93044	79645035
Haemorrhage subcutaneous	33.30	20.75	13	6296	4796	79733283
Liver disorder	32.34	20.75	34	6275	72383	79665696
Aortic dissection	31.45	20.75	12	6297	4163	79733916
Hypercalcaemic nephropathy	31.01	20.75	4	6305	4	79738075
Oesophageal carcinoma recurrent	29.33	20.75	5	6304	61	79738018
Disseminated intravascular coagulation	28.01	20.75	23	6286	35819	79702260
Drug eruption	27.84	20.75	25	6284	43910	79694169
Periodontitis	27.11	20.75	11	6298	4485	79733594
Pneumocystis jirovecii pneumonia	25.70	20.75	21	6288	32487	79705592
Iron deficiency anaemia	25.54	20.75	19	6290	25653	79712426
Anaemia	24.44	20.75	84	6225	444931	79293148
Fracture	23.64	20.75	17	6292	21784	79716295
Ulna fracture	23.53	20.75	7	6302	1138	79736941
Compression fracture	23.28	20.75	11	6298	6449	79731630
Physical deconditioning	23.28	20.75	8	6301	2062	79736017
Blood pressure decreased	22.23	20.75	33	6276	99433	79638646
Pyrexia	22.11	20.75	109	6200	678600	79059479
Nephrocalcinosis	21.65	20.75	7	6302	1495	79736584

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D050071	Bone Density Conservation Agents
CHEBI has role	CHEBI:25212	metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteoporosis	indication	64859006	DOID:11476

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.2	acidic
pKa2	13.89	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST				UNKNOWN	KEGG DRUG
Vitamin D3 receptor	Transcription factor		VDR_RAT	AGONIST	Kd	8		IUPHAR

External reference:

ID	Source
I2JP8UE90H	UNII
D07578	KEGG_DRUG
C2828245	UMLSCUI
CHEBI:73927	CHEBI
ED9	PDB_CHEM_ID
CHEMBL4297608	ChEMBL_ID
6918141	PUBCHEM_CID
DB05295	DRUGBANK_ID
8867	INN_ID
2783	IUPHAR_LIGAND_ID
C547512	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None